RTP Mobile Logo
Hematologic Oncology Update, Issue 2, 2011
Released September 2011

Featuring interviews with Drs Brad S Kahl, David J Straus, Elias Jabbour and Carol Ann Huff. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.

    LEARNING OBJECTIVES

    • Optimize the management of chronic lymphocytic leukemia through the rational integration of prospective pivotal data sets.
    • Counsel patients with follicular lymphoma about recent advances in induction and maintenance systemic treatment.
    • Apply the results of emerging clinical research to the care of patients with myelodysplastic syndromes.
    • Develop a treatment approach for younger and older patients with mantle-cell lymphoma based on recent clinical trial data.
    • Outline the classification of T-cell lymphomas, and formulate up-to-date treatment strategies for patients with diverse subtypes of the disease.
    • Summarize the critical factors in selecting patients with chronic myelogenous leukemia for treatment with first- and second-generation tyrosine kinase inhibitors.
    • Employ an understanding of recent findings with proteasome inhibitors and immunomodulatory agents in individualized induction and maintenance therapy for patients with multiple myeloma.
    • Describe the biologic rationale, efficacy and toxicity of novel agents targeting CD30-positive Hodgkin lymphoma and anaplastic large cell lymphoma.
    • Facilitate patient access to clinical trial participation through communication of ongoing research opportunities.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY


    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY
    — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr KahlAdvisory Committee: Celgene Corporation, Cephalon Inc, Genentech BioOncology; Consulting Agreements: Celgene Corporation, Roche Laboratories Inc. Dr StrausConsulting Agreements: Centocor Ortho Biotech Services LLC, Novartis Pharmaceuticals Corporation, Sanofi, Schering-Plough Corporation; Paid Research: Centocor Ortho Biotech Services LLC, Merck and Company Inc. Dr JabbourHonoraria: Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation. Dr HuffAdvisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Johnson & Johnson Pharmaceuticals, Onyx Pharmaceuticals Inc; Paid Research: Bristol-Myers Squibb Company, Geron.

    EDITOR
    Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx
    Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS
    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Allos Therapeutics, Celgene Corporation, Cephalon Inc, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Sanofi and Seattle Genetics.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: September 2011
    Expiration date: September 2012

Acknowledge and close

Listen to audio:
Hematologic Oncology Update, Issue 2, 2011
Released September 2011

Featuring interviews with Drs Brad S Kahl, David J Straus, Elias Jabbour and Carol Ann Huff. (Text and Audio Content)

Read print: